Search results

  1. Sid

    Graded exercise therapy compared to activity management for paediatric [CFS/ME]: pragmatic randomized controlled trial, 2024, Gaunt, Crawley et al.

    I can't say I've seen such a thing, except Crawley's LP trial and Magenta. Ultimately, it's up to the ethics committee to stop such inappropriate proposals so the real question here is why she was allowed to conduct such studies.
  2. Sid

    What PEM is like at relatively high physical function

    Same here. Transitioning from moderate (flu-like malaise PEM) to severe (extreme dysautonomia) was a terrifying experience. It occurred rather suddenly too, which made me think I was dying.
  3. Sid

    Brian Walitt and his role leading ME/CFS research at the USA NIH

    Yep. Lay members of the public have no idea how difficult it is to prove research misconduct or to get journals to take action even when proven. I know of papers that are still up despite clear-cut research fraud like falsified methods or authorship theft which the journals have been informed...
  4. Sid

    Deep phenotyping of post-infectious myalgic encephalomyelitis/chronic fatigue syndrome, 2024, Walitt et al

    This section highlights how they think. ME/CFS is a diagnosis of exclusion and if some “real” disease is found in your body, you can’t also have ME/CFS. Some of the other diseases they used to exclude people from the study have nothing to do with our symptoms like childhood epilepsy etc.
  5. Sid

    Graded exercise therapy compared to activity management for paediatric [CFS/ME]: pragmatic randomized controlled trial, 2024, Gaunt, Crawley et al.

    It’s very surprising to see this trial so transparently reported. Perhaps the huge pushback on SMILE (and the whole debacle of having nearly the whole article corrected post-publication) made them think it wasn’t worth going through the same hassle this time. Magenta results are so bad there’s...
  6. Sid

    Graded exercise therapy compared to activity management for paediatric [CFS/ME]: pragmatic randomized controlled trial, 2024, Gaunt, Crawley et al.

    Most making a good or complete recovery? How are they able to get away with these shameless statements?
  7. Sid

    Graded exercise therapy compared to activity management for paediatric [CFS/ME]: pragmatic randomized controlled trial, 2024, Gaunt, Crawley et al.

    I'd like to know if they're still using GET (or whatever euphemism they're using these days to circumvent the NICE guidelines) in their clinical service after seeing these results.
  8. Sid

    Use of EEfRT in the NIH study: Deep phenotyping of PI-ME/CFS, 2024, Walitt et al

    Going down this route will also allow them to focus on the stigmatising bit and give a lecture on dualism, ignoring the stronger and most important points about pwME/CFS being unable to complete the hard tasks and therefore the measure is not a measure of preference.
  9. Sid

    Who is Simon Wessely?

    People with very severe psychiatric disorders also have an inability to eat/drink or mobilise so it's very easy to dismiss severe ME/CFS as psychiatric because the test results are all "normal".
  10. Sid

    Who is Simon Wessely?

    It's literally the same CBT formulation they use for anxiety disorders such as agoraphobia with panic attacks. They think nothing is wrong other than the brain learning to associate physical symptoms of anxiety with activity which then leads to avoidance behaviour.
  11. Sid

    Graded exercise therapy compared to activity management for paediatric [CFS/ME]: pragmatic randomized controlled trial, 2024, Gaunt, Crawley et al.

    So they stopped recruitment in 2018, had the results in 2019 (1-year follow-up) and have been sitting on them for 5 years, quietly offloading them in an obscure low-impact journal with no press coverage. It's unethical to not publish trial results in a timely fashion. Also, any GET trials still...
  12. Sid

    Graded exercise therapy compared to activity management for paediatric [CFS/ME]: pragmatic randomized controlled trial, 2024, Gaunt, Crawley et al.

    Crawley in her 2016 letter makes several audacious statements about lack of any side effects: The letter sounds even more sinister in hindsight now that we have the results. I doubt those 27% of participants who ended up harmed by GET in MAGENTA enjoyed it.
  13. Sid

    Graded exercise therapy compared to activity management for paediatric [CFS/ME]: pragmatic randomized controlled trial, 2024, Gaunt, Crawley et al.

    It takes very little to harm people with GET. There have been anecdotal reports of people who went from moderate to severe after just one session.
  14. Sid

    Graded exercise therapy compared to activity management for paediatric [CFS/ME]: pragmatic randomized controlled trial, 2024, Gaunt, Crawley et al.

    They're going to have a hard time spinning this as GET and activity management being "equally effective" since neither was effective and the scores didn't budge in either group. It looks like it took them 9 years since trial registration to conduct the trial and report it. My goodness. I wonder...
  15. Sid

    NICE guideline on ME/CFS: robust advice based on a thorough review of the evidence, 2024, Barry et al.

    It's the go-to website for neurologists when confronted with patients whose symptoms they can't explain. Lots of reports on social media of being given a scribbled note with Stone's website written on it and told to go away and never come back.
  16. Sid

    Use of EEfRT in the NIH study: Deep phenotyping of PI-ME/CFS, 2024, Walitt et al

    Reaching out to Treadway is a good idea as long as the letter is laser focused on the misinterpretation of the EEfRT task, not the wider ME/CFS politics of the study. I don't know him but generally most civilians have been very reluctant (to put it mildly) to wade into ME/CFS waters. You could...
  17. Sid

    Anomalies in the review process and interpretation of the evidence in the NICE guideline for (CFS & ME), 2023, White et al

    Government and insurance industry trying to minimise long-term disability payments by denying that the illness exists. It really is as simple as that.
  18. Sid

    NICE guideline on ME/CFS: robust advice based on a thorough review of the evidence, 2024, Barry et al.

    Nothing to do with the journal. As an author, you can choose whether to make your paper open access or not. Keeping your paper behind a paywall is free while open access publishing is very expensive. I looked up what it costs at JNNP and it's nearly 4000 pounds. NICE obviously haven't chosen to...
Back
Top Bottom